Diabetes

Metabolic 14 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Metabolic indication. Diabetes has 14 FDA-approved novel treatments, led by Eli Lilly across 6 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Diabetes Market Leaders

Companies with the most FDA-approved novel Diabetes drugs.

Phase 3 Readouts Pro

10 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

PIEMONTE

EMS

Estimated · aging NCT05028140

Q3 2026

GZR4

Gan & Lee Pharmaceuticals.

Estimated · aging NCT06767735

Q4 2026

Exendin-4 Fc fusion protein injection(1.2mg）

Beijing Dongfang Biotech Co., Ltd.

Estimated · aging NCT06257966

Unlock 7 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Diabetes Treatments by Mechanism

Top 12 mechanisms across 190 industry trials with a known mechanism of action.

See full pipeline →

Sodium-Glucose Cotransporter 2 Inhibitor

6 trials 1 active 2 sponsors

GLP-1 Receptor Agonist

86 trials 3 sponsors

Insulin Analog

78 trials 7 sponsors

Dipeptidyl Peptidase 4 Inhibitor

6 trials 3 sponsors

SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose

5 trials 1 sponsor

Glinide

2 trials 1 sponsor

DPP-4

2 trials 1 sponsor

SGLT2

1 trials 1 sponsor

Corticosteroid

1 trials 1 sponsor

amylases/lipases/proteases

1 trials 1 sponsor

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist

1 trials 1 sponsor

PCSK9 Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Diabetes Clinical Pipeline by Phase

824 industry-sponsored trials across 207 sponsors

Showing 76 of 76 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Getz Pharma	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	RECRUITING	2026-12-31	NCT05164263
Nabiqasim Industries (Pvt) Ltd	—	—	RECRUITING	2026-04-30	NCT06862739
Dong Wha Pharmaceutical Co. Ltd.	DW6012(Dasidiem tab. 10/100mg)	—	RECRUITING	2025-12-31	NCT06875193
Les Laboratoires des Médicaments Stériles	switch NPH to glargin	—	NOT YET RECRUITING	2025-12-31	NCT06999551
Dong-A ST Co., Ltd.	DA-2811	—	COMPLETED	2025-03-10	NCT05743907
Johnson & Johnson Private Limited	Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)	—	COMPLETED	2022-07-26	NCT04288778
Getz Pharma	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2020-09-15	NCT04665284
Dong-A ST Co., Ltd.	Evogliptin	—	COMPLETED	2020-07-02	NCT03910361
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2019-08-05	NCT02730377
Yuhan Corporation	Rosuvastatin+Ezetimibe	—	COMPLETED	2019-04-03	NCT03217409
AstraZeneca	dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	COMPLETED	2019-03-19	NCT03387683
Sanofi	INSULIN GLARGINE (U300)	—	COMPLETED	2019-02-04	NCT03406000
Handok Inc.	Teneligliptin	—	COMPLETED	2018-09	NCT03011177
Dong-A ST Co., Ltd.	evogliptin	—	COMPLETED	2018-03	NCT02974504
GSK	Albiglutide 30 mg	—	COMPLETED	2018-02-20	NCT02465515
AstraZeneca	—	—	COMPLETED	2017-12-20	NCT02910089
Novo Nordisk	—	—	COMPLETED	2017-12-09	NCT02617693
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2017-03-18	NCT02582242
Takeda	Pioglitazone	—	COMPLETED	2016-10-17	NCT01972724
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2016-09-20	NCT02453685
Prof. Dr. Thomas Forst	Saxagliptin	—	COMPLETED	2016-08	NCT02304081
Materia Medica Holding	Subetta	—	COMPLETED	2016-07	NCT01868594
Materia Medica Holding	Subetta	—	COMPLETED	2016-06-15	NCT01868646
Profil Institut für Stoffwechselforschung GmbH	Linagliptin	Dipeptidyl Peptidase 4 Inhibitor [EPC]	COMPLETED	2016-04	NCT01903070
LifeScan	—	—	COMPLETED	2016-04	NCT02429024
Novartis	LAF237 (vildagliptin)	—	COMPLETED	2015-10-22	NCT01766778
AstraZeneca	Farxiga	SGLT2	COMPLETED	2015-10	NCT02429258
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2015-07-09	NCT01589653
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-06-15	NCT01907854
Novo Nordisk	insulin detemir	Insulin Analog [EPC]	COMPLETED	2015-05	NCT01868542
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2014-11	NCT02008682
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2014-11	NCT01973231
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2014-09-01	NCT01917656
Novartis	Vildagliptin	—	COMPLETED	2014-09	NCT01686932
Chemical Resources	—	—	COMPLETED	2014-05	NCT02700477
AstraZeneca	Saxagliptin	—	COMPLETED	2014-05	NCT01608724
Novo Nordisk	biphasic insulin aspart 50	—	COMPLETED	2014-05	NCT01892020
Profil Institut für Stoffwechselforschung GmbH	—	—	COMPLETED	2014-01	NCT01730885
Takeda	AD-4833 15 mg	—	COMPLETED	2013-12	NCT01686711
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2013-10	NCT01519674
Abbott Diabetes Care	—	—	COMPLETED	2013-05	NCT01713348
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2013-04	NCT01066039
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2013-01	NCT01618214
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2012-09	NCT01215435
Novartis	vildagliptin	—	COMPLETED	2012-08	NCT00894868
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2012-07	NCT01427920
Novartis	Vildagliptin	—	COMPLETED	2012-06	NCT01398592
Novo Nordisk	insulin detemir	Insulin Analog [EPC]	COMPLETED	2012-05	NCT01068652
Novo Nordisk	insulin aspart	Insulin Analog [EPC]	COMPLETED	2012-04	NCT01165684
Novo Nordisk	Insulin detemir	Insulin Analog [EPC]	COMPLETED	2011-11-01	NCT01232491
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2011-09	NCT01278160
Vantive Health LLC	Physioneal	—	COMPLETED	2011-07	NCT00567489
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2011-06	NCT01123980
Takeda	Pioglitazone and Metformin	—	COMPLETED	2011-05	NCT00770835
Novo Nordisk	Insulin-Levemir	—	COMPLETED	2011-04	NCT01076842
Novo Nordisk	repaglinide	Glinide [EPC]	COMPLETED	2010-11	NCT01022762
Novo Nordisk	insulin detemir	Insulin Analog [EPC]	COMPLETED	2010-08	NCT00795600
Takeda	Pioglitazone and insulin	—	COMPLETED	2010-07	NCT00770445
Novo Nordisk	insulin detemir	Insulin Analog [EPC]	COMPLETED	2010-06	NCT00909480
Novartis	Amlodipine	—	COMPLETED	2010-01	NCT00787605
Novo Nordisk	repaglinide	Glinide [EPC]	COMPLETED	2009-11	NCT00819741
Merck	sitagliptin phosphate	DPP-4	COMPLETED	2009-10-30	NCT00833027
Novo Nordisk	biphasic insulin aspart 30	—	COMPLETED	2009-10	NCT00807092
Novo Nordisk	insulin detemir	Insulin Analog [EPC]	COMPLETED	2008-10	NCT00634842
GSK	Albiglutide 50mg	—	TERMINATED	2017-08-10	NCT02802514
Novo Nordisk	insulin detemir	Insulin Analog [EPC]	TERMINATED	2012-06	NCT01486966
Novartis	Valturna	—	TERMINATED	2012-02	NCT01368536
Merck	sitagliptin	Dipeptidyl Peptidase 4 Inhibitor [EPC]	TERMINATED	2009-09-02	NCT00832624
Bracco Diagnostics, Inc	Iopamidol injection 76%	—	TERMINATED	2009-09	NCT00782639
Colgate Palmolive	Stannous Fluoride Dentifrice	—	ENROLLING BY INVITATION	2028-01-02	NCT07619729
Ascension Health	Dexamethasone	Corticosteroid [EPC]	WITHDRAWN	2020-12-31	NCT03646916
AstraZeneca	Dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	WITHDRAWN	2017-11	NCT02719132
Abbott	Creon	amylases/lipases/proteases	WITHDRAWN	2014-08	NCT02009410
LifeScan	—	—	WITHDRAWN	2013-06	NCT01631643
Merck KGaA, Darmstadt, Germany	Glucophage	—	WITHDRAWN	2012-06	NCT01510522
Medtronic - MITG	—	—	WITHDRAWN	2009-01	NCT00596973

Showing 100 of 236 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Gan & Lee Pharmaceuticals.	GZR4	—	RECRUITING	2026-11-10	NCT07165223
Pfizer	PF-08653944	—	RECRUITING	2027-10-12	NCT07400653
Kailera	KAI-9531	—	RECRUITING	2028-03-27	NCT07284901
Novo Nordisk	NNC0487-0111	—	RECRUITING	2028-08-07	NCT07533175
Khondrion BV	Sonlicromanol	—	RECRUITING	2028-09	NCT06451757
EMS	PIEMONTE	—	RECRUITING	2026-07	NCT05028140
EMS	BERLIM 25/20 ASSOCIATION	—	RECRUITING	2026-05	NCT04602754
Energenesis Biomedical Co., Ltd.	ENERGI-F703 GEL	—	RECRUITING	2025-12-30	NCT05930210
Gan & Lee Pharmaceuticals.	GZR4	—	ACTIVE NOT RECRUITING	2026-08-01	NCT06767735
Beijing Dongfang Biotech Co., Ltd.	Exendin-4 Fc fusion protein injection(1.2mg）	—	ACTIVE NOT RECRUITING	2026-10-01	NCT06257966
Gan & Lee Pharmaceuticals.	GZR4	—	ACTIVE NOT RECRUITING	2026-03-19	NCT06767761
Gan & Lee Pharmaceuticals.	GZR4	—	ACTIVE NOT RECRUITING	2026-02-07	NCT06767748
Eli Lilly	Orforglipron	—	NOT YET RECRUITING	2027-05	NCT07613307
HK inno.N Corporation	IN-B00009	—	NOT YET RECRUITING	2027-08	NCT07308184
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	aleniglipron	—	NOT YET RECRUITING	2028-09	NCT07654374
Eli Lilly	Retatrutide	—	COMPLETED	2026-01-22	NCT06354660
Novo Nordisk	Insulin icodec	—	COMPLETED	2025-05-08	NCT06340854
Sunshine Lake Pharma Co., Ltd.	Insulin Degludec and Insulin Aspart	—	COMPLETED	2024-08-16	NCT05802862
Eli Lilly	Tirzepatide Dose 1	—	COMPLETED	2024-07-30	NCT05260021
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	COMPLETED	2024-07-01	NCT05691712
Eli Lilly	Insulin Efsitora Alfa	—	COMPLETED	2024-05-07	NCT05463744
Eli Lilly	Insulin Efsitora Alfa	—	COMPLETED	2024-04-10	NCT05362058
AJU Pharm Co., Ltd.	AJU-A51	—	COMPLETED	2022-12-01	NCT06329674
Eli Lilly	Dulaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2022-10-01	NCT04809220
Boryung Pharmaceutical Co., Ltd	Metformin≥1000mg	—	COMPLETED	2022-09-19	NCT04885712
Dong-A ST Co., Ltd.	Evogliptin 5mg	—	COMPLETED	2021-06-28	NCT04170998
Novo Nordisk	Insulin degludec	Insulin Analog [EPC]	COMPLETED	2020-12-17	NCT03377699
Chong Kun Dang Pharmaceutical	CKD-501 0.5mg	—	COMPLETED	2020-05-25	NCT03739125
Geropharm	GP40071	—	COMPLETED	2020-01-21	NCT04079413
Merck	Sitagliptin	Dipeptidyl Peptidase 4 Inhibitor [EPC]	COMPLETED	2019-10-09	NCT01485614
Novo Nordisk	Insulin degludec/liraglutide	—	COMPLETED	2019-06-14	NCT03172494
Valbiotis	—	—	COMPLETED	2019-04	NCT02868177
Novo Nordisk	Semaglutide 0.5 mg	—	COMPLETED	2019-03-14	NCT03061214
Novo Nordisk	Insulin degludec/liraglutide	—	COMPLETED	2019-03-05	NCT03175120
Geropharm	Lantus Solostar, 100 Units/mL Subcutaneous Solution	—	COMPLETED	2019-02-25	NCT04022993
Novo Nordisk	Insulin degludec	Insulin Analog [EPC]	COMPLETED	2019-02-13	NCT03078478
Biocon Limited	Insulin Tregopil	—	COMPLETED	2019-02-06	NCT03430856
Theracos	Bexagliflozin tablets, 20 mg	—	COMPLETED	2019-01-23	NCT03259789
Geropharm	Humalog Mix25	—	COMPLETED	2019-01-15	NCT04023344
Novo Nordisk	Faster-acting insulin aspart	—	COMPLETED	2019-01-07	NCT03268005
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-10-16	NCT03136484
Novo Nordisk	insulin degludec/liraglutide	—	COMPLETED	2018-10-03	NCT02501161
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-09-25	NCT02692716
AstraZeneca	Dapagliflozin 10 mg	—	COMPLETED	2018-09-11	NCT01730534
Eli Lilly	LY900014	—	COMPLETED	2018-09-04	NCT03433677
Eli Lilly	Glucagon Nasal Powder	—	COMPLETED	2018-08-20	NCT03421379
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-07-12	NCT03015220
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-07-09	NCT03191396
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-07-04	NCT03086330
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-05-04	NCT02964247
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-04-10	NCT02827708
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-02-28	NCT02849080
Novo Nordisk	Faster-acting insulin aspart	—	COMPLETED	2018-02-05	NCT02670915
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-01-18	NCT03021187
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-01-09	NCT03018028
Novo Nordisk	insulin degludec/liraglutide	—	COMPLETED	2017-12-15	NCT02607306
Amgen	Evolocumab	PCSK9 Inhibitor [EPC]	COMPLETED	2017-12-06	NCT02662569
Novo Nordisk	Insulin degludec/liraglutide	—	COMPLETED	2017-11-17	NCT02911948
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2017-11-15	NCT01541215
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2017-10-30	NCT02906930
Novo Nordisk	insulin degludec/liraglutide	—	COMPLETED	2017-09-26	NCT02773368
Novo Nordisk	Insulin degludec/insulin aspart	—	COMPLETED	2017-08-31	NCT02906917
AstraZeneca	Saxagliptin	—	COMPLETED	2017-08-29	NCT02419612
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2017-08-19	NCT02863419
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2017-08-01	NCT02863328
Novo Nordisk	Faster-acting insulin aspart	—	COMPLETED	2017-07-17	NCT02500706
Yuhan Corporation	YH14755	—	COMPLETED	2017-07-07	NCT02586129
Novo Nordisk	Faster-acting insulin aspart	—	COMPLETED	2017-06-20	NCT02825251
Novo Nordisk	insulin degludec/insulin aspart	—	COMPLETED	2017-05-19	NCT02762578
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2017-05-02	NCT02505334
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2017-04-10	NCT02648204
Daewoong Pharmaceutical Co. LTD.	Metformin/Atorvastatin 1500mg/40mg, QD	—	COMPLETED	2017-02-27	NCT02947620
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2017-02-14	NCT02607865
Dompé Farmaceutici S.p.A	Reparixin	—	COMPLETED	2016-12	NCT01817959
Novo Nordisk	insulin degludec	Insulin Analog [EPC]	COMPLETED	2016-10-16	NCT01959529
Novo Nordisk	insulin degludec/liraglutide	—	COMPLETED	2016-10-05	NCT02420262
Novo Nordisk	insulin degludec/insulin aspart	—	COMPLETED	2016-09-04	NCT02648217
AstraZeneca	Exenatide	—	COMPLETED	2016-08-29	NCT02229383
Tonghua Dongbao Pharmaceutical Co.,Ltd	insulin Aspart injection	—	COMPLETED	2016-08-12	NCT02491528
AstraZeneca	Exantide with Dapagliflozin	—	COMPLETED	2016-04-26	NCT02229396
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2016-03-15	NCT01720446
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2016-02-27	NCT02207374
AstraZeneca	Dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	COMPLETED	2016-01-28	NCT02096705
Novo Nordisk	insulin degludec	Insulin Analog [EPC]	COMPLETED	2016-01-11	NCT02034513
Novo Nordisk	insulin degludec/liraglutide	—	COMPLETED	2015-12-23	NCT02298192
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-12-17	NCT01179048
Novo Nordisk	insulin degludec	Insulin Analog [EPC]	COMPLETED	2015-12-04	NCT02030600
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-11-21	NCT02305381
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-11-11	NCT02254291
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-10-12	NCT01930188
InQpharm Group	—	—	COMPLETED	2015-10	NCT02541344
Merck	Omarigliptin	—	COMPLETED	2015-09-14	NCT01814748
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-09-03	NCT02128932
Takeda	Alogliptin	—	COMPLETED	2015-09	NCT01890122
Eli Lilly	Nasal Glucagon	—	COMPLETED	2015-08	NCT02171130
Eli Lilly	Nasal Glucagon	—	COMPLETED	2015-08	NCT02402933
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-07-13	NCT01885208
Novo Nordisk	liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-06	NCT01836523
Novo Nordisk	Faster-acting insulin aspart	—	COMPLETED	2015-05-12	NCT01831765
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-05-08	NCT02054897

Showing 100 of 166 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Corxel Pharmaceuticals	CX11	—	RECRUITING	2026-12-23	NCT07340320
Hudson Biotech	MOTS-c (MDP)	—	RECRUITING	2027-02-14	NCT07505745
Sun Pharmaceutical Industries Limited	GL0034 Dose Level 1	—	RECRUITING	2027-04	NCT07282743
Otsuka Pharmaceutical Factory, Inc.	—	—	RECRUITING	2027-06-30	NCT06575426
Thomas Advanced Medical LLC	PrimePro™/ PrimeMSK™	—	RECRUITING	2030-07-09	NCT04684602
PolTREG S.A.	ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)	—	RECRUITING	2032-12	NCT06688331
Op-T LLC	OPT101	—	RECRUITING	2026-05-31	NCT06964087
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.	Fuling Yunhua Granules	—	RECRUITING	2025-01-30	NCT06575478
Golo	—	—	RECRUITING	2024-11	NCT05844644
Admetsys Corporation	—	—	ACTIVE NOT RECRUITING	2026-11	NCT01291719
AstraZeneca	AZD6234	—	ACTIVE NOT RECRUITING	2026-05-27	NCT06851858
BrightGene Bio-Medical Technology Co., Ltd.	BGM0504 tablets	—	NOT YET RECRUITING	2027-02-28	NCT07658560
Xantho Biotechnology Co., LTD	GM-XANTHO	—	NOT YET RECRUITING	2028-12-31	NCT05199077
Altheia Science	—	—	NOT YET RECRUITING	2029-06-15	NCT06938334
Pfizer	MET097 Injection	—	COMPLETED	2025-12-29	NCT06897202
Unity Biotechnology, Inc.	Aflibercept	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2025-01-21	NCT06011798
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	GSBR-1290	—	COMPLETED	2024-04-11	NCT05762471
Aphaia Pharma US LLC	APHD-012	—	COMPLETED	2024-02-12	NCT05803772
Oxurion	THR-149 dose level 1	—	COMPLETED	2023-09-28	NCT04527107
Khondrion BV	Oral administration of 100 mg KH176 twice daily	—	COMPLETED	2023-06-01	NCT04604548
WinSanTor, Inc	Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution	—	COMPLETED	2022-12-08	NCT04786340
Bayer	BAY2395840	—	COMPLETED	2022-11-07	NCT05219812
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Polysaccharide superparamagnetic iron oxide injection	—	COMPLETED	2022-06-13	NCT06051565
Lexicon Pharmaceuticals	LX9211	—	COMPLETED	2022-05-23	NCT04455633
CuraLife	—	—	COMPLETED	2022-04-01	NCT05439473
Youngene Therapeutics Inc., Ltd.	YG1699	—	COMPLETED	2022-02-02	NCT04956263
Novartis	Inclisiran	—	COMPLETED	2021-12-17	NCT03060577
Pfizer	PF-06882961	—	COMPLETED	2021-11-17	NCT04617275
Precigen Actobio T1D, LLC	AG019 - Low Dose	—	COMPLETED	2021-10-13	NCT03751007
REMD Biotherapeutics, Inc.	REMD-477	—	COMPLETED	2021-03-05	NCT03117998
NextCell Pharma Ab	ProTrans	—	COMPLETED	2020-12-10	NCT03973827
Neuraly, Inc.	NLY01	—	COMPLETED	2020-12-04	NCT04159766
Diamyd Medical AB	Diamyd	—	COMPLETED	2020-07-13	NCT03345004
NextCell Pharma Ab	ProTrans: Allogeneic transplantation with WJMSCs	—	COMPLETED	2020-07-01	NCT03406585
Xeris Pharmaceuticals	PRAM9	—	COMPLETED	2020-04-02	NCT04074317
Oramed, Ltd.	Oral Insulin	—	COMPLETED	2020-03-01	NCT02653300
Charsire Biotechnology Corp.	CSTC1	—	COMPLETED	2020-01-07	NCT01813305
MedImmune LLC	MEDI0382	—	COMPLETED	2019-12-22	NCT03596177
Eli Lilly	LY900014	—	COMPLETED	2019-10-07	NCT03760640
Energenesis Biomedical Co., Ltd.	ENERGI-F703	—	COMPLETED	2019-10-03	NCT02672436
Boston Therapeutics	BTI320	—	COMPLETED	2019-08-30	NCT03655535
Oxurion	Ranibizumab 0.5mg	—	COMPLETED	2019-07-18	NCT03499223
Esperion Therapeutics, Inc.	Bempedoic acid + Ezetimibe FDC Oral Tablet	—	COMPLETED	2019-06-18	NCT03531905
Dompé Farmaceutici S.p.A	Ladarixin	—	COMPLETED	2019-05-15	NCT02814838
Sanofi	Sotagliflozin (SAR439954)	—	COMPLETED	2019-04-18	NCT03462069
Lisata Therapeutics, Inc.	CLBS03 Low Dose	—	COMPLETED	2019-03	NCT02691247
MedImmune LLC	MEDI0382	—	COMPLETED	2019-02-04	NCT03550378
GeNeuro Australia PTY Ltd	GNbAC1	—	COMPLETED	2018-09-01	NCT03179423
Novo Nordisk	NNC0114-0006	—	COMPLETED	2018-08-31	NCT02443155
AbbVie	Atrasentan	—	COMPLETED	2018-04-18	NCT02118714
Millennium Pharmaceuticals, Inc.	TAK-906 Maleate	—	COMPLETED	2018-03-09	NCT03268941
Diasome Pharmaceuticals	HDV insulin lispro 100 UNIT/mL	—	COMPLETED	2018-01-15	NCT03156361
REMD Biotherapeutics, Inc.	REMD-477	—	COMPLETED	2018-01	NCT02455011
Liminal BioSciences Ltd.	PBI-4050	—	COMPLETED	2017-09-26	NCT02739217
The Medicines Company	ALN-PCSSC	—	COMPLETED	2017-06-07	NCT02597127
NovMetaPharma Co., Ltd.	Cyclo-Z	—	COMPLETED	2017-05-03	NCT02784275
Zealand Pharma	ZP4207(dasiglucagon) glucagon analogue	—	COMPLETED	2017-04-05	NCT02916251
Kamada, Ltd.	Alpha-1 Antitrypsin	—	COMPLETED	2017-02	NCT02005848
Oshadi Drug Administration	Oshadi Icp	—	COMPLETED	2017-02	NCT01973920
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2016-10-13	NCT02461589
Astellas	ASP8232	—	COMPLETED	2016-08-12	NCT02302079
Oramed, Ltd.	ORMD-0801	—	COMPLETED	2016-06-27	NCT02496000
AbbVie	Relamorelin	—	COMPLETED	2016-06-09	NCT02357420
Novo Nordisk	insulin 338 (GIPET I)	—	COMPLETED	2015-12-31	NCT02470039
TheraVasc Inc.	Sodium nitrite	Cytochrome a3/Hemoglobin	COMPLETED	2015-12-07	NCT02412852
AstraZeneca	Omega-3 carboxylic acids	—	COMPLETED	2015-12	NCT02279407
Bristol-Myers Squibb	BMS-986036	—	COMPLETED	2015-09-22	NCT02097277
Novo Nordisk	Liraglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2015-09-15	NCT02205528
BioDelivery Sciences International	clonidine hydrochloride topical gel, 0.1%	—	COMPLETED	2015-08	NCT02355158
ANS Pharma	Diacerein	—	COMPLETED	2015-08	NCT03208309
Pfizer	PF-06291874	—	COMPLETED	2015-03	NCT02175121
Osprey Medical, Inc	Timentin	—	COMPLETED	2015-02	NCT02158442
Tris Pharma, Inc.	Cebranopadol 100 µg	—	COMPLETED	2015-01	NCT01939366
Yuhan Corporation	YH14617	—	COMPLETED	2015-01	NCT01507038
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2014-12-11	NCT01923181
Adocia	BioChaperone human insulin	—	COMPLETED	2014-12	NCT02213146
Biodel	BIOD-531	—	COMPLETED	2014-11	NCT02324309
Profil Institut für Stoffwechselforschung GmbH	Insulin LISPRO	Insulin Analog [EPC]	COMPLETED	2014-11	NCT02221323
Profil Institut für Stoffwechselforschung GmbH	Luyxumia versus Lantus	—	COMPLETED	2014-10	NCT01910194
NGM Biopharmaceuticals, Inc	NGM282	—	COMPLETED	2014-09	NCT01943045
DiaMedica Therapeutics Inc	DM199	—	COMPLETED	2014-09	NCT01845064
Oramed, Ltd.	ORMD-0801 Capsules	—	COMPLETED	2014-08	NCT02094534
Adocia	BioChaperone insulin lispro 0.2U/Kg	—	COMPLETED	2014-07	NCT02146651
Resverlogix Corp	RVX000222	—	COMPLETED	2014-03	NCT01728467
DIApedia, LLC	—	—	COMPLETED	2013-12	NCT00803608
Theracos	EGT0001442	—	COMPLETED	2013-11	NCT01377844
Oramed, Ltd.	ORMD-0801 Dose # 1	—	COMPLETED	2013-11	NCT01889667
Novartis	Sitagliptin	Dipeptidyl Peptidase 4 Inhibitor [EPC]	COMPLETED	2013-09	NCT01619332
GSK	GSK1070806	—	COMPLETED	2013-09	NCT01648153
Roche	aleglitazar	—	COMPLETED	2013-09	NCT01729403
Roche	aleglitazar	—	COMPLETED	2013-09	NCT01680978
Motus Therapeutics, Inc.	RM-131	—	COMPLETED	2013-08	NCT01571297
Hanmi Pharmaceutical Company Limited	HM11260C	—	COMPLETED	2013-06	NCT01452451
Oshadi Drug Administration	Oshadi Icp	—	COMPLETED	2013-06	NCT01772251
Amgen	AMG 151	—	COMPLETED	2012-10	NCT01464437
Cebix Incorporated	CBX129801	—	COMPLETED	2012-08	NCT01293461
Roche	aleglitazar	—	COMPLETED	2012-07	NCT01043029
Becton, Dickinson and Company	—	—	COMPLETED	2012-05	NCT01557907
Pfizer	150 mg PF-04991532	—	COMPLETED	2012-03	NCT01336738
Ascension Health	—	—	COMPLETED	2012-01	NCT01354262

Showing 100 of 346 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Sun Pharmaceutical Industries Limited	GL0034	—	RECRUITING	2026-09	NCT07385547
Eli Lilly	Retatrutide	—	RECRUITING	2026-11	NCT06982859
Jiangsu HengRui Medicine Co., Ltd.	SHR-3167 Injection	—	RECRUITING	2026-12	NCT07489482
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531 Injection	—	RECRUITING	2027-01	NCT07540754
Novo Nordisk	NNC0487-0111	—	RECRUITING	2027-11-11	NCT07535307
Ono Pharmaceutical Co., Ltd.	ONO-3310	—	RECRUITING	2027-11-30	NCT07619157
Hangzhou Reprogenix Bioscience, Inc	RGB-5088	—	RECRUITING	2027-12-31	NCT06731218
Boryung Pharmaceutical Co., Ltd	Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg	—	RECRUITING	2026-07-03	NCT07083388
Rezubio Pharmaceuticals Co., Ltd.	RZ-629	—	RECRUITING	2025-12-20	NCT06829563
Jiangsu HengRui Medicine Co., Ltd.	HR011408 injection; HR011408 injection Placebo	—	RECRUITING	2024-07-01	NCT06375031
Gan & Lee Pharmaceuticals.	GZR4	—	ACTIVE NOT RECRUITING	2026-07-14	NCT07193147
Korea United Pharm. Inc.	Administration of UI087	—	NOT YET RECRUITING	2026-08	NCT07548957
Otsuka Pharmaceutical Development & Commercialization, Inc.	NDI-5001	—	NOT YET RECRUITING	2027-04-14	NCT07525960
Immunocore Ltd	IMC-S118AI	—	NOT YET RECRUITING	2030-11	NCT07493122
Addpharma Inc.	AD-123	—	NOT YET RECRUITING	2026-05	NCT07538466
AJU Pharm Co., Ltd.	Comparator 1	—	NOT YET RECRUITING	2025-11	NCT07044765
AJU Pharm Co., Ltd.	Comparator 1	—	NOT YET RECRUITING	2025-11	NCT07034781
Shandong Suncadia Medicine Co., Ltd.	HRS-7535 Tables	—	COMPLETED	2026-01-22	NCT06961643
Vivani Medical, Inc	Bydureon BCise (exenatide extended release)	—	COMPLETED	2025-08-21	NCT05670379
Lexaria Bioscience Corp.	Arm 1 - DehydraTECH-CBD alone	—	COMPLETED	2025-07-31	NCT06648031
Gedeon Richter Plc.	Empagliflozin + Metformin hydrochloride 12.5 mg/1000 mg combination film-coated tablets	—	COMPLETED	2025-05-21	NCT06823856
Gedeon Richter Plc.	Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets	—	COMPLETED	2025-04-06	NCT06792968
Gedeon Richter Plc.	Empagliflozin + Metformin hydrochloride 5 mg/850 mg combination film-coated tablets	—	COMPLETED	2025-02-28	NCT06766500
Shandong Suncadia Medicine Co., Ltd.	HRS-7535 tablets	—	COMPLETED	2025-01-25	NCT06727838
Zhejiang Anglikang Pharmaceutical Co., Ltd.	BM2216 Extended-Release tablets（5.5mg）	—	COMPLETED	2025-01-04	NCT06846567
Chong Kun Dang Pharmaceutical	CKD-379	—	COMPLETED	2024-12-04	NCT06652971
Tonghua Dongbao Pharmaceutical Co.,Ltd	THDBH120 injection	—	COMPLETED	2024-11-27	NCT07020949
Hua Medicine Limited	HM-002-1005	—	COMPLETED	2024-09-06	NCT06498284
Gan and Lee Pharmaceuticals, USA	GZR4	—	COMPLETED	2024-08-20	NCT06547502
Carmot Therapeutics, Inc.	CT-388	—	COMPLETED	2024-06-18	NCT04838405
Huons Co., Ltd.	HUC2-344	—	COMPLETED	2024-06-10	NCT06551740
Chong Kun Dang Pharmaceutical	CKD-378, QD, PO	—	COMPLETED	2024-06-03	NCT06386328
Atrogi AB	ATR-258 Oral solution	—	COMPLETED	2024-05-27	NCT06432673
Boryung Pharmaceutical Co., Ltd	BR3005	—	COMPLETED	2024-04-03	NCT06289933
Huons Co., Ltd.	HUC2-344	—	COMPLETED	2024-02-15	NCT06552182
Humanis Saglık Anonim Sirketi	Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets	—	COMPLETED	2024-01-16	NCT06450262
Gan and Lee Pharmaceuticals, USA	GZR4	—	COMPLETED	2023-11-01	NCT06553248
Jiangsu HengRui Medicine Co., Ltd.	HR011408 injection; NovoRapid®	—	COMPLETED	2023-10-26	NCT05737576
Boryung Pharmaceutical Co., Ltd	BR3006-1	—	COMPLETED	2023-09-11	NCT05951946
Chong Kun Dang Pharmaceutical	CKD-378, QD, PO Drug: D745, D150, QD, PO	—	COMPLETED	2023-08-31	NCT05741437
Chong Kun Dang Pharmaceutical	D745, D759, D150	—	COMPLETED	2023-08-29	NCT05928637
Humanis Saglık Anonim Sirketi	Empagliflozin film coated tablets	—	COMPLETED	2023-08-27	NCT06180109
Jiangsu HengRui Medicine Co., Ltd.	INS062 injection、INS068 injection、HR20014 injection	—	COMPLETED	2023-07-18	NCT05887895
Chong Kun Dang Pharmaceutical	CKD-378 (low-dose)	—	COMPLETED	2023-06-28	NCT05881213
Vicore Pharma AB	C21	—	COMPLETED	2023-06-16	NCT05831644
Gan and Lee Pharmaceuticals, USA	GZR4	—	COMPLETED	2023-03-24	NCT06548815
Chong Kun Dang Pharmaceutical	CKD-379	—	COMPLETED	2023-03-23	NCT05719155
CRISPR Therapeutics AG	—	—	COMPLETED	2023-01-19	NCT05210530
Neuraly, Inc.	DD01	—	COMPLETED	2022-12-20	NCT04812262
AstraZeneca	Experimental: Cotadutide	—	COMPLETED	2022-12-12	NCT05437848
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	TG103 injection	—	COMPLETED	2022-12-01	NCT04855292
Chong Kun Dang Pharmaceutical	CKD-371	—	COMPLETED	2022-11-14	NCT05544214
Chong Kun Dang Pharmaceutical	CKD-379 I	—	COMPLETED	2022-08-27	NCT05452525
Youngene Therapeutics Inc., Ltd.	YG1699	—	COMPLETED	2022-08-12	NCT05089617
Chong Kun Dang Pharmaceutical	CKD-393	—	COMPLETED	2022-07-15	NCT05274880
Jiangsu HengRui Medicine Co., Ltd.	INS068 injection	—	COMPLETED	2022-05-26	NCT05336071
Retinset SL	Bosentan	ETA/ETB	COMPLETED	2022-05-20	NCT04068272
Chong Kun Dang Pharmaceutical	CKD-393(2)	—	COMPLETED	2022-05-02	NCT05347576
Carmot Therapeutics, Inc.	CT-868 as SC Injection	—	COMPLETED	2022-04-22	NCT04973111
Sparrow Pharmaceuticals	SPI-62	—	COMPLETED	2022-03-10	NCT05409027
Goldfinch Bio, Inc.	GFB-024	—	COMPLETED	2022-02-08	NCT04880291
Jiangsu HengRui Medicine Co., Ltd.	HR011408 injection	—	COMPLETED	2022-01-22	NCT05147259
Pfizer	PF-07081532	—	COMPLETED	2021-07-14	NCT04305587
Chong Kun Dang Pharmaceutical	CKD-501, D745, D150	—	COMPLETED	2021-05-20	NCT04810676
Immunomolecular Therapeutics, Inc.	350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule	—	COMPLETED	2021-05-11	NCT04625595
Chong Kun Dang Pharmaceutical	CKD-393 formulation I	—	COMPLETED	2021-04-22	NCT04768673
Sichuan Haisco Pharmaceutical Group Co., Ltd	[14C]HSK7653	—	COMPLETED	2021-01-14	NCT04540016
Richmond Research Institute	Moxifloxacin	—	COMPLETED	2020-12-31	NCT01984827
Hanmi Pharmaceutical Company Limited	HM15136	—	COMPLETED	2020-12-09	NCT04167553
ThromboGenics	THR-687 dose level 1	—	COMPLETED	2019-11-20	NCT03666923
Jiangsu HengRui Medicine Co., Ltd.	Hydrochlorothiazide、Henagliflozin Proline	—	COMPLETED	2019-10-10	NCT06083116
Chong Kun Dang Pharmaceutical	Part A, Reference (D635 10/500mg, Astrazeneca)	—	COMPLETED	2019-08-30	NCT04156685
Sanofi	Sotagliflozin (SAR439954)	—	COMPLETED	2019-08-19	NCT03909451
DiaMedica Therapeutics Inc	DM199	—	COMPLETED	2019-07-21	NCT03795389
Gan and Lee Pharmaceuticals, USA	Gan & Lee Insulin Lispro Injection	—	COMPLETED	2019-07-03	NCT04235439
Suzhou Yabao Pharmaceutical R&D Co., Ltd.	SY-009	—	COMPLETED	2019-05-30	NCT04119947
Stratatech, a Mallinckrodt Company	ExpressGraft-C9T1 Skin Tissue	—	COMPLETED	2019-05-28	NCT02657876
ThromboGenics	THR-149 dose level 1	—	COMPLETED	2019-05-22	NCT03511898
Dong-A ST Co., Ltd.	DA-1229_01(A), Sugamet SR Tab 5/1000mg®	—	COMPLETED	2019-04-04	NCT03939143
Dong-A ST Co., Ltd.	DA-1229_01(A), Sugamet SR Tab 5/1000mg®	—	COMPLETED	2019-03-25	NCT03944200
Boryung Pharmaceutical Co., Ltd	Treatment A (Fimasartan, Linagliptin)	—	COMPLETED	2019-03-04	NCT03609294
Jeil Pharmaceutical Co., Ltd.	"Metformin" and "Rosuvastatin" seperately	—	COMPLETED	2019-02-01	NCT03690778
Dong-A ST Co., Ltd.	Evogliptin→Evogliptin+Empagliflozin→Empagliflozin	—	COMPLETED	2019-01-18	NCT03766724
Suzhou Yabao Pharmaceutical R&D Co., Ltd.	SY-008	—	COMPLETED	2018-12-30	NCT03462589
Theracos	Bexagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2018-12-26	NCT03557658
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-10-19	NCT02773381
Chong Kun Dang Pharmaceutical	D308, CKD-501	—	COMPLETED	2018-09-17	NCT03616392
Novo Nordisk	Semaglutide 0.5 mg	—	COMPLETED	2018-07-10	NCT03288740
Novo Nordisk	Semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2018-07-10	NCT03466567
Novo Nordisk	Faster aspart	—	COMPLETED	2018-07-05	NCT03407599
Genexine, Inc.	Gx-G6	—	COMPLETED	2018-06-06	NCT03651466
Novo Nordisk	NNC9204-1513	—	COMPLETED	2018-05-24	NCT03444467
Sanofi	Sotagliflozin (SAR439954)	—	COMPLETED	2018-03-10	NCT03414723
Eli Lilly	Insulin Lispro	Insulin Analog [EPC]	COMPLETED	2018-02-09	NCT03367390
Novo Nordisk	insulin degludec/liraglutide	—	COMPLETED	2018-01-02	NCT03292185
Novo Nordisk	Faster-acting insulin aspart	—	COMPLETED	2017-12-21	NCT02933853
Novo Nordisk	Insulin icodec	—	COMPLETED	2017-12-12	NCT02964104
VitNovo, Inc.	DCB-DM101	—	COMPLETED	2017-12	NCT03033433
Novo Nordisk	semaglutide	GLP-1 Receptor Agonist [EPC]	COMPLETED	2017-11-24	NCT02877355
Novo Nordisk	Faster-acting insulin aspart	—	COMPLETED	2017-11-20	NCT03215498

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Diabetes

PR (Progesterone Receptor) (5) Factor VIII coagulant activity >5% (1) Factor VIII levels >5% (1) albuminuria >300 mg/day (1)

Novel Diabetes Drugs by Company (New molecular entities)

5 companies have an FDA-approved novel drug for Diabetes.

Eli Lilly 4 drugs

HUMALOG KWIKPEN

INSULIN LISPRO RECOMBINANT

BLA 1996

HUMALOG TEMPO PEN

INSULIN LISPRO RECOMBINANT

BLA 1996

HUMALOG

INSULIN LISPRO RECOMBINANT

Sanofi 4 drugs

INSULIN GLULISINE RECOMBINANT

BLA 2004

APIDRA

INSULIN GLULISINE RECOMBINANT

BLA 2004

LANTUS SOLOSTAR

INSULIN GLARGINE RECOMBINANT

BLA 2000

LANTUS

INSULIN GLARGINE RECOMBINANT

Novo Nordisk 4 drugs

INSULIN ASPART PROTAMINE RECOMBINANT

BLA 2001

NOVOLOG

INSULIN ASPART RECOMBINANT

BLA 2000

ZEALAND PHARMA 1 drug

ZEGALOGUE

DASIGLUCAGON HYDROCHLORIDE

NDA 2021

SANOFI-AVENTIS U.S. LLC 1 drug

MERILOG SOLOSTAR

INSULIN ASPART-SZJJ

BLA 2025

Reformulations (14 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Diabetes Drug Targets

Molecular targets of approved and investigational Diabetes drugs — 6 targets tracked.

Insulin receptor 16 HMGCR 3 Glucagon receptor 2 DGAT 1 Lipoprotein lipase 1 NPC1L1 1

Biosimilars (4 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

SANOFI-AVENTIS U.S. LLC

2020